DelveInsight’s, “Neurofibrosarcoma Pipeline Insight 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Neurofibrosarcoma pipeline landscape. It covers the Neurofibrosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neurofibrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Neurofibrosarcoma Pipeline Report to explore emerging therapies, key Neurofibrosarcoma Companies, and future Neurofibrosarcoma treatment landscapes @ Neurofibrosarcoma Pipeline Outlook Report

Key Takeaways from the Neurofibrosarcoma Pipeline Report

• In April 2025, University of Florida conducted a phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
• In April 2025, Alexander Z. Wei, MD announced a phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
• DelveInsight’s Neurofibrosarcoma Ppipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Neurofibrosarcoma treatment.
• The leading Neurofibrosarcoma Companies such as Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
• Promising Neurofibrosarcoma Pipeline Therapies such as Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.

Stay ahead with the most recent pipeline outlook for Neurofibrosarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neurofibrosarcoma Treatment Drugs

Neurofibrosarcoma Emerging Drugs Profile

• NFX-179: NFlection Therapeutics

NFX-179 is an investigational mitogen-activated protein kinase kinase (MEK) inhibitor. NFX-179 is a “”soft”” (metabolically labile) drug, which, when formulated as NFX-179 Gel for topical application, is designed to concentrate at the dermal site of action but degrade in systemic circulation, thereby significantly reducing side effects compared to systemically available MEK inhibitors.

• Sirolimus: Nobelpharma

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus: FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

The Neurofibrosarcoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibrosarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibrosarcoma treatment.
• Neurofibrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neurofibrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibrosarcoma market.

Explore groundbreaking therapies and clinical trials in the Neurofibrosarcoma Pipeline. Access DelveInsight’s detailed report now! @ New Neurofibrosarcoma Drugs

Neurofibrosarcoma Companies

Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.

Neurofibrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Neurofibrosarcoma Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Unveil the future of Neurofibrosarcoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neurofibrosarcoma Market Drivers and Barriers

Scope of the Neurofibrosarcoma Pipeline Report

• Coverage- Global
• Neurofibrosarcoma Companies- Daiichi Sankyo, Chia Tai Tianqing Pharmaceutical Group, Mirati Therapeutics, Astex Pharmaceuticals, Ascentage Pharma Group, Apexigen, Nobelpharma, Pfizer, SpringWorks Therapeutics, NFlection Therapeutics and others.
• Neurofibrosarcoma Pipeline Therapies- Ganetespib, Sirolimus, everolimus, bevacizumab, Selumetinib, Tazemetostat, Dasatinib, Doxorubicin, APX005M and others.
• Neurofibrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Neurofibrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Neurofibrosarcoma Drug development? Find out in DelveInsight’s exclusive Neurofibrosarcoma Pipeline Report—access it now! @ Neurofibrosarcoma Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Neurofibrosarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neurofibrosarcoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Sirolimus: Nobelpharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ASTX727: Astex Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. MRTX1719: Mirati Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Neurofibrosarcoma Key Companies
21. Neurofibrosarcoma Key Products
22. Neurofibrosarcoma- Unmet Needs
23. Neurofibrosarcoma- Market Drivers and Barriers
24. Neurofibrosarcoma- Future Perspectives and Conclusion
25. Neurofibrosarcoma Analyst Views
26. Neurofibrosarcoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/neurofibrosarcoma-pipeline-insight